Alzheimer’s Dementia: The Emerging Role of Positron Emission Tomography

Shailendra Tripathi; Alison Murray

doi:10.1177/1073858421997035

Alzheimer’s Dementia: The Emerging Role of Positron Emission Tomography

Shailendra Tripathi^* (Corresponding Author), Alison Murray

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

13 Citations (Scopus)

7 Downloads (Pure)

Abstract

Alzheimer’s disease (AD) is the most common cause of dementia and accounts for approximately 50% to 80% of all cases of dementia. The diagnosis of probable AD is based on clinical criteria and overlapping clinical features pose a challenge to accurate diagnosis. However, neuroimaging has been included as a biomarker in various published criteria for the diagnosis of probable AD, in the absence of a confirmatory diagnostic test during life. Advances in neuroimaging techniques and their inclusion in diagnostic and research criteria for the diagnosis of AD includes the use of positron emission tomography (PET) imaging as a biomarker in various therapeutic and prognostic studies in AD. The development and application of a range of PET tracers will allow more detailed assessment of people with AD and will improve diagnostic specificity and targeted therapy of AD. The aim of this review is to summarize current evidence on PET imaging using the non-specific tracer [18F]fluorodeoxyglucose and specific tracers that target amyloid and tau pathology in people with AD.

Original language	English
Number of pages	13
Journal	The Neuroscientist
Volume	28
Issue number	5
Early online date	4 Mar 2021
DOIs	https://doi.org/10.1177/1073858421997035
Publication status	Published - 1 Oct 2022

Bibliographical note

Open Access via Sage Agreement

Keywords

Alzheimer’s disease
amyloid and tau pathology
neuroimaging
positron emission tomography
tracers

Access to Document

10.1177/1073858421997035Licence: CC BY-NC

Tripathi_etal_TN_Alzheimer_Dementia_The_VoR
https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Final published version, 1.12 MBLicence: CC BY-NC

Cite this

@article{7150bd49c24f411aac6903b1110602de,

title = "Alzheimer{\textquoteright}s Dementia: The Emerging Role of Positron Emission Tomography",

abstract = "Alzheimer{\textquoteright}s disease (AD) is the most common cause of dementia and accounts for approximately 50% to 80% of all cases of dementia. The diagnosis of probable AD is based on clinical criteria and overlapping clinical features pose a challenge to accurate diagnosis. However, neuroimaging has been included as a biomarker in various published criteria for the diagnosis of probable AD, in the absence of a confirmatory diagnostic test during life. Advances in neuroimaging techniques and their inclusion in diagnostic and research criteria for the diagnosis of AD includes the use of positron emission tomography (PET) imaging as a biomarker in various therapeutic and prognostic studies in AD. The development and application of a range of PET tracers will allow more detailed assessment of people with AD and will improve diagnostic specificity and targeted therapy of AD. The aim of this review is to summarize current evidence on PET imaging using the non-specific tracer [18F]fluorodeoxyglucose and specific tracers that target amyloid and tau pathology in people with AD.",

keywords = "Alzheimer{\textquoteright}s disease, amyloid and tau pathology, neuroimaging, positron emission tomography, tracers",

author = "Shailendra Tripathi and Alison Murray",

note = "Open Access via Sage Agreement",

year = "2022",

month = oct,

day = "1",

doi = "10.1177/1073858421997035",

language = "English",

volume = "28",

journal = "The Neuroscientist",

issn = "1073-8584",

publisher = "SAGE Publications Inc.",

number = "5",

}

TY - JOUR

T1 - Alzheimer’s Dementia

T2 - The Emerging Role of Positron Emission Tomography

AU - Tripathi, Shailendra

AU - Murray, Alison

N1 - Open Access via Sage Agreement

PY - 2022/10/1

Y1 - 2022/10/1

N2 - Alzheimer’s disease (AD) is the most common cause of dementia and accounts for approximately 50% to 80% of all cases of dementia. The diagnosis of probable AD is based on clinical criteria and overlapping clinical features pose a challenge to accurate diagnosis. However, neuroimaging has been included as a biomarker in various published criteria for the diagnosis of probable AD, in the absence of a confirmatory diagnostic test during life. Advances in neuroimaging techniques and their inclusion in diagnostic and research criteria for the diagnosis of AD includes the use of positron emission tomography (PET) imaging as a biomarker in various therapeutic and prognostic studies in AD. The development and application of a range of PET tracers will allow more detailed assessment of people with AD and will improve diagnostic specificity and targeted therapy of AD. The aim of this review is to summarize current evidence on PET imaging using the non-specific tracer [18F]fluorodeoxyglucose and specific tracers that target amyloid and tau pathology in people with AD.

AB - Alzheimer’s disease (AD) is the most common cause of dementia and accounts for approximately 50% to 80% of all cases of dementia. The diagnosis of probable AD is based on clinical criteria and overlapping clinical features pose a challenge to accurate diagnosis. However, neuroimaging has been included as a biomarker in various published criteria for the diagnosis of probable AD, in the absence of a confirmatory diagnostic test during life. Advances in neuroimaging techniques and their inclusion in diagnostic and research criteria for the diagnosis of AD includes the use of positron emission tomography (PET) imaging as a biomarker in various therapeutic and prognostic studies in AD. The development and application of a range of PET tracers will allow more detailed assessment of people with AD and will improve diagnostic specificity and targeted therapy of AD. The aim of this review is to summarize current evidence on PET imaging using the non-specific tracer [18F]fluorodeoxyglucose and specific tracers that target amyloid and tau pathology in people with AD.

KW - Alzheimer’s disease

KW - amyloid and tau pathology

KW - neuroimaging

KW - positron emission tomography

KW - tracers

UR - http://www.scopus.com/inward/record.url?scp=85102152776&partnerID=8YFLogxK

U2 - 10.1177/1073858421997035

DO - 10.1177/1073858421997035

M3 - Review article

SN - 1073-8584

VL - 28

JO - The Neuroscientist

JF - The Neuroscientist

IS - 5

ER -

Alzheimer’s Dementia: The Emerging Role of Positron Emission Tomography

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this